Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Policy / Pricing
  • Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients
  • Policy / Pricing

Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients

BioSpace

With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner's National Priority Vouchers this week, it's full speed ahead for psychedelics.

Policy / PricingNeuroscienceRead full story

pharminent April 22, 2026 (Last updated: April 22, 2026)

BioSpace

With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics.

Policy / PricingNeuroscienceRead full story

Post navigation

Previous: Neurology, biomanufacturing start-ups bag UK AI funding
Next: Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

Related Stories

  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.